Special Issue "Combining Immunotherapy with Radiotherapy for Cancer Treatment: Current Challenges and Future Directions"
Deadline for manuscript submissions: 28 January 2023 | Viewed by 1086
Interests: radiotherapy; immunotherapy; inflammation; regulatory T cells; lung cancer; head and neck cancer
Undoubtedly, the treatment of cancer will continue to require multimodal therapy for the forseeable future. The combination of two major pillars of cancer treatment, radiotherapy and immunotherapy, has opened the door to numerous treatment possibilities. Each pillar is unique in its own way and advancing at a fast rate. Yet, radioimmunotherapy (RIT) also presents a unique set of challenges: When should RIT be used and what criteria should be applied? What type of immunotherapy should be used in combination with RT? What dose and fractionation regimen should be used with a selected immunotherapy? How should the two therapies be arranged and at what frequency: sequential, concurrent? Which cell population(s) is involved with each therapy and how do these cell populations interact when the two therapies are combined? What pathways are implicated and does acquired resistance develop? These are some of the questions that need to be addressed in order to advance the field of RIT. In this Special Issue, titled Combining Immunotherapy with Radiotherapy for Cancer Treatment: Current Challenges and Future Directions, we wish to shed light on the emerging field of RIT. We are eager to read your submissions and publish them in this Special Issue.
Dr. Ayman J. Oweida
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune checkpoint blockade
- stereotactic ablative radiotherapy
- abscopal effect
- immune cells
- adaptive immunity
- innate immunity